Skip to content

Reference

Evidence

CompoundsSubstances with curated findings
OutcomesMeasured endpoints
ProteinsTransporters and enzymes
InteractionsPairs that share biology
PapersEvery paper a finding cites

Reference layer

PathwaysReactions grouped under one name
ProcessesWhat proteins are annotated as doing
AnatomyTissues, by what is expressed there
Cell typesCells, by what is expressed there
OrganismsSpecies a compound is prepared from
MaterialsSubstances that are not one molecule
AssessmentsRegulatory determinations, transcribed

Atlas Graph Access

Search the graph

Atlas Graph Access Compounds Outcomes Proteins Interactions Papers Pathways Processes Anatomy Cell types Organisms Materials Assessments

Loading the page.

Catalyst

The evidence graph for human biochemistry. Every edge carries its source, its study design, and a grade computed from both.

A reference for what the literature reports. Not medical advice.

© 2026 CatalystPrivacy Terms

Reference data under the licences listed on the attribution page.

The graph

Compounds
Outcomes
Proteins
Atlas
Interactions
Papers
Graph
Search

Reference layer

Pathways
Processes
Anatomy
Cell types
Organisms
Materials
Assessments

How it works

Mission
Method
How to read the evidence
Sources and licences

Build on it

Access
For agents
Query the graph
Bulk export

Papers/PMID:34294550

The Effects of Cholecalciferol Supplementation on FGF23 and α-Klotho in Hemodialysis Patients With Hypovitaminosis D: A Randomized, Double-Blind, Placebo-Controlled Trial.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation2022The record

1 finding drawn from this paper, on 1 compound across 1 endpoint.

calciol

What it reported

How to read these marks

What moved

1 finding

calciol — increases serum 25-hydroxyvitamin D concentration
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Findingreplicated ×9
“Serum 25OH(D) levels increased in participants who received cholecalciferol supplementation compared with participants who received placebo (P = .006).”
Quoted verbatim from The Effects of Cholecalciferol Supplementation on FGF23 and α-Klotho in Hemodialysis Patients With Hypovitaminosis D: A Randomized, Double-Blind, Placebo-Controlled Trial..
Study

RCT
Duration

3 months
Dose

50,000 IU cholecalciferol weekly for 12 weeks
Population

Hemodialysis patients with hypovitaminosis D
The Effects of Cholecalciferol Supplementation on FGF23 and α-Klotho in Hemodialysis Patients With Hypovitaminosis D: A Randomized, Double-Blind, Placebo-Controlled Trial.2022PMID:34294550